Coelho Rogerio Vivaldi
CIK 1610381 · PRESIDENT AND CEO · last filed 2026-03-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.52M
Companies
6
Total Filings
32
Lifetime Open-Market Net
-$3.57M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 16,823 | $34.47 | $579.9K | -$70.5K | 8 | 2026-03-13 |
| VTRS | Director | 45,351 | $16.48 | $747.4K | $0 | 4 | 2026-03-10 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | PRESIDENT AND CEO | 0 | $22.47 | $0 | $0 | 8 | 2023-08-11 |
| Bioverativ Inc. (BIVV) Delisted | EVP, Chief Global Therapeutics | 0 | — | — | $0 | 5 | 2018-03-08 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Chief Commercial Officer | 20,116 | — | — | -$3.75M | 6 | 2016-07-19 |
| NERV | President and CEO | 41,667 | $4.51 | $187.9K | $250.0K | 1 | 2014-07-09 |
Recent Filings · Page 4 of 4
32 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-02-06 | Spark Therapeutics, Inc. (ONCE) Delisted | Buy (P) | +2,500 | $57.5K | EDGAR |
| 2014-07-09 | NERV | Mixed | +41,667 | $250.0K | EDGAR |
Showing 31–32 of 32
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.